iRhythm Technologies Gestion

Gestion contrôle des critères 2/4

Le PDG iRhythm Technologies est Quentin Blackford, nommé en Oct2021, a un mandat de 3.08 ans. La rémunération annuelle totale est $ 16.60M, composée du salaire de 4.1% et des bonus 95.9%, y compris les actions et options de la société. détient directement 0.26% des actions de la société, d'une valeur de € 6.26M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.5 ans et 7.3 ans.

Informations clés

Quentin Blackford

Directeur général

US$16.6m

Rémunération totale

Pourcentage du salaire du PDG	4.1%
Durée du mandat du directeur général	3.1yrs
Propriété du PDG	0.3%
Durée moyenne d'occupation des postes de direction	2.5yrs
Durée moyenne du mandat des membres du conseil d'administration	7.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Quentin Blackford a-t-elle évolué par rapport aux bénéfices de iRhythm Technologies?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$151m
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$130m
Dec 31 2023	US$17m	US$677k	-US$123m
Sep 30 2023	n/a	n/a	-US$105m
Jun 30 2023	n/a	n/a	-US$99m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$8m	US$650k	-US$116m
Sep 30 2022	n/a	n/a	-US$128m
Jun 30 2022	n/a	n/a	-US$131m
Mar 31 2022	n/a	n/a	-US$124m
Dec 31 2021	US$10m	US$163k	-US$101m

Rémunération vs marché: La rémunération totale de Quentin ($USD 16.60M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.95M ).

Rémunération et revenus: La rémunération de Quentin a augmenté alors que l'entreprise n'est pas rentable.

PDG

Quentin Blackford (45 yo)

3.1yrs

Titularisation

US$16,595,149

Compensation

Mr. Quentin S. Blackford serves as an Independent Director of Paragon 28, Inc. since August 1, 2022. He serves as President and Chief Executive Officer since October 04, 2021 and serves as Director at iRhy...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Quentin Blackford	President	3.1yrs	US$16.60m	0.26% € 6.3m
Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	2.6yrs	US$5.32m	0.015% € 370.5k
Patrick Murphy	Chief Business & Legal Officer	2.9yrs	US$5.33m	0.031% € 730.0k
Chad Patterson	Chief Commercial Officer	2.3yrs	US$5.77m	0.025% € 600.8k
Mervin Smith	Executive Vice President of Business Operations	1.3yrs	pas de données	0.0023% € 56.0k
Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	1.3yrs	pas de données	0.0029% € 69.4k
Daniel Wilson	Executive VP of Corporate Development & Investor Relations	5.4yrs	US$3.54m	0.098% € 2.3m
Sumi Shrishrimal	Executive VP & Chief Risk Officer	2.5yrs	pas de données	0.074% € 1.8m
Stephanie Zhadkevich	Director of Investor Relations	no data	pas de données	pas de données

2.5yrs

Durée moyenne de l'emploi

45yo

Âge moyen

Gestion expérimentée: L'équipe de direction de I25 est considérée comme expérimentée (ancienneté moyenne 2.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Quentin Blackford	President	2.8yrs	US$16.60m	0.26% € 6.3m
Ralph Snyderman	Independent Director	7.3yrs	US$233.12k	0.032% € 771.1k
Michael Mirro	Medical Director & Member of Scientific Advisory Board	no data	pas de données	pas de données
Bruce Bodaken	Independent Director	7.3yrs	US$240.25k	0.030% € 721.4k
Abhijit Talwalkar	Independent Chairman	8.5yrs	US$286.74k	0.055% € 1.3m
R. Mead	Medical Director & Member of Scientific Advisory Board	no data	pas de données	pas de données
James Quinn	Member of Scientific Advisory Board	no data	pas de données	pas de données
Cathleen Noel Merz	Independent Director	6.6yrs	US$230.62k	0.018% € 441.3k
Mark Rubash	Independent Director	8.7yrs	US$248.12k	0.034% € 809.1k
Mehdi Razavi	Medical Director & Member of Scientific Advisory Board	no data	pas de données	pas de données
Karen Ling	Independent Director	3yrs	US$239.97k	0.020% € 486.7k
Jay Alexander	Medical Director & Member of Scientific Advisory Board	no data	pas de données	pas de données

7.3yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de I25 sont considérés comme expérimentés (ancienneté moyenne 7.3 ans).

iRhythm Technologies Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

President recently sold €1.1m worth of stock

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

President recently sold €2.8m worth of stock

Insider recently sold €680k worth of stock

Executive VP & Chief Risk Officer recently sold €115k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

Recent updates

President recently sold €1.1m worth of stock

Third quarter 2024 earnings released: US$1.48 loss per share (vs US$0.89 loss in 3Q 2023)

iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device

iRhythm Technologies, Inc. to Report Q3, 2024 Results on Oct 30, 2024

New minor risk - Profitability

iRhythm Technologies, Inc. Reaffirms Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. Announces Results of GUARD-AF Trial

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.65 loss per share (vs US$0.61 loss in 2Q 2023)

Irhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024

iRhythm Technologies, Inc. Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

Forecast to breakeven in 2026

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q1, 2024 Results on May 02, 2024

New minor risk - Profitability

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

New minor risk - Shareholder dilution

President recently sold €2.8m worth of stock

Forecast to breakeven in 2026

Full year 2023 earnings released: US$4.04 loss per share (vs US$3.88 loss in FY 2022)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against iRhythm Technologies, Inc

iRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024

Insider recently sold €680k worth of stock

iRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.89 loss per share (vs US$0.71 loss in 3Q 2022)

iRhythm Technologies, Inc. to Report Q3, 2023 Results on Nov 02, 2023

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.80 loss in 2Q 2022)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Full Year 2023

iRhythm Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Executive VP & Chief Risk Officer recently sold €115k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$1.29 loss per share (vs US$1.71 loss in 1Q 2022)

Now 23% undervalued

COO & Secretary recently sold €391k worth of stock

Full year 2022 earnings released: US$3.88 loss per share (vs US$3.46 loss in FY 2021)

iRhythm Technologies, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Chief Legal Counsel recently sold €174k worth of stock

President recently sold €1.6m worth of stock

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.71 loss per share (vs US$0.81 loss in 3Q 2021)

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2022

iRhythm Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022

iRhythm Technologies, Inc. Reiterates Revenue Guidance for the Year 2022

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.59 loss in 2Q 2021)

iRhythm Technologies, Inc. Appoints Brice Bobzien as Chief Financial Officer, Effective August 8, 2022

iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System

iRhythm Technologies, Inc. Announces Management Changes

Executive Vice President of Strategy recently sold €152k worth of stock

Independent Director recently sold €54k worth of stock

First quarter 2022 earnings released: US$1.71 loss per share (vs US$0.95 loss in 1Q 2021)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

iRhythm Technologies, Inc. to Report Q1, 2022 Results on May 05, 2022

iRhythm Technologies, Inc., Annual General Meeting, May 26, 2022

iRhythm Technologies, Inc. Announces the Results of Three Clinical Research Studies Presented At the American College of Cardiology’s 71 Annual Scientific Session & Expo

Consultant & Director recently sold €828k worth of stock

iRhythm Technologies, Inc. Announces the Results of the KP-Rhythm2 Study

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

COO, CFO & Secretary recently sold €490k worth of stock

iRhythm Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.17 loss in 3Q 2020)